✉ Email this page to a colleague
« Back to Dashboard
Aminophylline is a drug marketed by Abraxis Pharm, Am Regent, Elkins Sinn, Hospira, Intl Medication, King Pharms, Luitpold, Lyphomed, Pharma Serve Ny, Smith And Nephew, Teva Parenteral, Morton Grove, Roxane, Impax Labs, Tablicaps, Vale, Ani Pharms, Ascot, Barr, Duramed Pharms Barr, Halsey, Hikma Intl Pharms, Kv Pharm, Lannett, Pal Pak, Panray, Purepac Pharm, Valeant Pharm Intl, Vangard, Vintage Pharms, Watson Labs, and Actavis Mid Atlantic. and is included in fifty-eight NDAs.
The generic ingredient in AMINOPHYLLINE is aminophylline. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the aminophylline profile page.
A generic version of AMINOPHYLLINE was approved as aminophylline by HOSPIRA on October 26th, 1983.
Recent Clinical Trials for AMINOPHYLLINE
Identify potential brand extensions & 505(b)(2) entrants
|Sengkang General Hospital||Phase 2|
|Singapore General Hospital||Phase 2|
|Beni-Suef University||Phase 1|
Pharmacology for AMINOPHYLLINE
|Drug Class||Methylxanthine |
Medical Subject Heading (MeSH) Categories for AMINOPHYLLINE
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Kv Pharm||AMINOPHYLLINE||aminophylline||TABLET;ORAL||085284-001||Approved Prior to Jan 1, 1982||DISCN||No||No||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|Barr||AMINOPHYLLINE||aminophylline||TABLET;ORAL||088297-001||Aug 19, 1983||DISCN||No||No||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|Purepac Pharm||AMINOPHYLLINE||aminophylline||TABLET;ORAL||085333-001||Approved Prior to Jan 1, 1982||DISCN||No||No||See Plans and Pricing||See Plans and Pricing||See Plans and Pricing|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|